These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 15649254)
1. EPHA2/EFNA1 expression in human gastric cancer. Nakamura R; Kataoka H; Sato N; Kanamori M; Ihara M; Igarashi H; Ravshanov S; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Konno H; Shinmura K; Tanaka M; Sugimura H Cancer Sci; 2005 Jan; 96(1):42-7. PubMed ID: 15649254 [TBL] [Abstract][Full Text] [Related]
2. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Kataoka H; Igarashi H; Kanamori M; Ihara M; Wang JD; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Maruyama K; Nakamura T; Arai H; Kajimura M; Hanai H; Tanaka M; Sugimura H Cancer Sci; 2004 Feb; 95(2):136-41. PubMed ID: 14965363 [TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner. Hong HN; Won YJ; Shim JH; Kim HJ; Han SH; Kim BS; Kim HS J Cancer Res Clin Oncol; 2018 Sep; 144(9):1649-1663. PubMed ID: 29948146 [TBL] [Abstract][Full Text] [Related]
4. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Cui XD; Lee MJ; Yu GR; Kim IH; Yu HC; Song EY; Kim DG Int J Cancer; 2010 Feb; 126(4):940-9. PubMed ID: 19642143 [TBL] [Abstract][Full Text] [Related]
5. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563 [TBL] [Abstract][Full Text] [Related]
6. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Wykosky J; Gibo DM; Stanton C; Debinski W Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188 [TBL] [Abstract][Full Text] [Related]
7. EphA2/ephrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland. Shao Z; Zhu F; Song K; Zhang H; Liu K; Shang Z J Oral Maxillofac Surg; 2013 May; 71(5):869-78. PubMed ID: 23298804 [TBL] [Abstract][Full Text] [Related]
8. Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Potla L; Boghaert ER; Armellino D; Frost P; Damle NK Cancer Lett; 2002 Jan; 175(2):187-95. PubMed ID: 11741747 [TBL] [Abstract][Full Text] [Related]
9. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Nasreen N; Mohammed KA; Lai Y; Antony VB Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899 [TBL] [Abstract][Full Text] [Related]
10. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer. Lee PC; Chen ST; Kuo TC; Lin TC; Lin MC; Huang J; Hung JS; Hsu CL; Juan HF; Lee PH; Huang MC Oncogene; 2020 Mar; 39(13):2724-2740. PubMed ID: 32005975 [TBL] [Abstract][Full Text] [Related]
11. Activation of erythropoietin-producing hepatocellular receptor A2 attenuates cell adhesion of human fallopian tube epithelial cells via focal adhesion kinase dephosphorylation. Yang XY; Zhu WJ; Jiang H Mol Cell Biochem; 2012 Feb; 361(1-2):259-65. PubMed ID: 22009484 [TBL] [Abstract][Full Text] [Related]
13. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene. Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143 [TBL] [Abstract][Full Text] [Related]
14. Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Yuan WJ; Ge J; Chen ZK; Wu SB; Shen H; Yang P; Hu B; Zhang GW; Chen ZH Dig Dis Sci; 2009 Nov; 54(11):2410-7. PubMed ID: 19101799 [TBL] [Abstract][Full Text] [Related]
15. Bidirectional signalling between EphA2 and ephrinA1 increases tubular cell attachment, laminin secretion and modulates erythropoietin expression after renal hypoxic injury. Rodriguez S; Rudloff S; Koenig KF; Karthik S; Hoogewijs D; Huynh-Do U Pflugers Arch; 2016 Aug; 468(8):1433-48. PubMed ID: 27228995 [TBL] [Abstract][Full Text] [Related]
16. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289 [TBL] [Abstract][Full Text] [Related]
17. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Han L; Dong Z; Qiao Y; Kristensen GB; Holm R; Nesland JM; Suo Z Gynecol Oncol; 2005 Nov; 99(2):278-86. PubMed ID: 16061279 [TBL] [Abstract][Full Text] [Related]
18. Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Yuan W; Chen Z; Wu S; Ge J; Chang S; Wang X; Chen J; Chen Z Pathol Oncol Res; 2009 Sep; 15(3):473-8. PubMed ID: 19048396 [TBL] [Abstract][Full Text] [Related]
19. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Xu F; Zhong W; Li J; Shanshen Z; Cui J; Nesland JM; Suo Z Anticancer Res; 2005; 25(4):2943-50. PubMed ID: 16080548 [TBL] [Abstract][Full Text] [Related]
20. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma. Toma MI; Erdmann K; Diezel M; Meinhardt M; Zastrow S; Fuessel S; Wirth MP; Baretton GB PLoS One; 2014; 9(7):e102262. PubMed ID: 25025847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]